Status:
UNKNOWN
Urin-based Point-of-Care Testing for Direct Oral Anticoagulants in Stroke Patients
Lead Sponsor:
University of Giessen
Conditions:
Stroke
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this study is to test a urine-based point-of-care testing device for direct oral anticoagulants in patients with stroke. The main questions are: * Can the test identify patients with dire...
Detailed Description
Stroke is the second leading cause of death worldwide and the most common cause of acquired disability in adulthood. During the acute phase of ischemic brain infarction, the goal of therapy is the rap...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient age ≥18 years at the time of admission
- Clinical diagnosis of ischemic or hemorrhagic stroke.
- Treatmet at our certified stroke-unit, University Hospital Giessen.
- Phase 1 only: Confirmed intake of a direct oral anticoagulant (DOAC) for at least 48 hours (test group) or no intake of a DOAC (control group for specificity determination)
- Phase II only, anamnestic intake of DOAC or no information about OAC-intake.
- Phase II only, presentation with 4.5 hours after onset.
- Exclusion Criteria (only Phase II):
- Contraindications for intravenous thrombolysis other than intake of DOAC
- large vessel occlusion with indication for immediate endovascular thrombectomy
- chronic renal insufficiency with need for hemodialysis
Exclusion
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06037200
Start Date
January 1 2023
End Date
July 31 2024
Last Update
September 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, University Hospital Giessen
Giessen, Hesse, Germany, 35392